These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy? Goto S Circ J; 2010 May; 74(5):850-1. PubMed ID: 20424335 [No Abstract] [Full Text] [Related]
8. The long and winding road to warfarin pharmacogenetic testing. Ginsburg GS; Voora D J Am Coll Cardiol; 2010 Jun; 55(25):2813-5. PubMed ID: 20579536 [No Abstract] [Full Text] [Related]
9. Genetic testing for warfarin dosing? Not yet ready for prime time. Bussey HI; Wittkowsky AK; Hylek EM; Walker MB Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960 [No Abstract] [Full Text] [Related]
10. Pharmacogenomic testing for warfarin dosing: we are ready now. Wu AH Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308 [No Abstract] [Full Text] [Related]
11. Warfarin and pharmacogenomic testing: what would Pascal do? Teagarden JR Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943 [No Abstract] [Full Text] [Related]
12. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Crawford DC; Ritchie MD; Rieder MJ Pharmacogenomics; 2007 May; 8(5):487-96. PubMed ID: 17465713 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic-based dosing of warfarin. Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958 [No Abstract] [Full Text] [Related]
14. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Carlquist JF; Anderson JL Circulation; 2011 Dec; 124(23):2554-9. PubMed ID: 22144632 [No Abstract] [Full Text] [Related]
15. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. Bodin L; Perdu J; Diry M; Horellou MH; Loriot MA J Thromb Haemost; 2008 Aug; 6(8):1436-9. PubMed ID: 18532998 [No Abstract] [Full Text] [Related]
17. The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Chan SL; Suo C; Chia KS; Teo YY Pharmacogenomics; 2012 Aug; 13(11):1247-56. PubMed ID: 22920395 [TBL] [Abstract][Full Text] [Related]
18. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population. Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335 [TBL] [Abstract][Full Text] [Related]
19. Prediction of warfarin dose: why, when and how? Eriksson N; Wadelius M Pharmacogenomics; 2012 Mar; 13(4):429-40. PubMed ID: 22379999 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Shrif NE; Won HH; Lee ST; Park JH; Kim KK; Kim MJ; Kim S; Lee SY; Ki CS; Osman IM; Rhman EA; Ali IA; Idris MN; Kim JW Eur J Clin Pharmacol; 2011 Nov; 67(11):1119-30. PubMed ID: 21590310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]